{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:57:34Z","timestamp":1792267054431,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005071","name":"Shiraz University","doi-asserted-by":"publisher","award":["22257"],"award-info":[{"award-number":["22257"]}],"id":[{"id":"10.13039\/501100005071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.parint.2025.103229","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:09:20Z","timestamp":1767168560000},"page":"103229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluating the efficacy of Glucantime and determinants of treatment success in cutaneous leishmaniasis: A retrospective study"],"prefix":"10.1016","volume":"112","author":[{"given":"Sahar","family":"Jamshidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasem","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.parint.2025.103229_bb0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect. Dis."},{"issue":"12","key":"10.1016\/j.parint.2025.103229_bb0010","article-title":"Cutaneous Leishmaniasis prevalence and clinical overview: a single center study from Saudi Arabia, eastern region, Al-Ahsa","volume":"8","author":"Al-Dhafiri","year":"2023","journal-title":"Trop. Med. Infect. Dis."},{"issue":"2","key":"10.1016\/j.parint.2025.103229_bb0015","first-page":"143","article-title":"Human cutaneous leishmaniosis in Iran, up to date-2019","volume":"15","author":"Razavi","year":"2021","journal-title":"J. Arthropod. Borne Dis."},{"key":"10.1016\/j.parint.2025.103229_bb0020","doi-asserted-by":"crossref","first-page":"1091709","DOI":"10.3389\/fpubh.2023.1091709","article-title":"Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan","volume":"11","author":"Sharifi","year":"2023","journal-title":"Front. Public Health"},{"issue":"Supple 1","key":"10.1016\/j.parint.2025.103229_bb0025","first-page":"28","article-title":"Incidence, burden, and trend of cutaneous leishmaniasis over four decades in Iran","volume":"48","author":"Piroozi","year":"2019","journal-title":"Iran. J. Public Health"},{"issue":"3","key":"10.1016\/j.parint.2025.103229_bb0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4269\/ajtmh.15-0408","article-title":"Social and economic burden of human Leishmaniasis","volume":"94","author":"Okwor","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.parint.2025.103229_bb0035","first-page":"10","article-title":"Epidemiological aspects of cutaneous Leishmaniasis in Iran","author":"Khazaei","year":"2015","journal-title":"Arch. Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.parint.2025.103229_bb0040","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40121-022-00602-2","article-title":"Treatment of cutaneous Leishmaniasis and insights into species-specific responses: a narrative review","volume":"11","author":"Madusanka","year":"2022","journal-title":"Infect. Dis. Ther."},{"issue":"2","key":"10.1016\/j.parint.2025.103229_bb0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jiph.2012.11.003","article-title":"Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran","volume":"6","author":"Mohammadzadeh","year":"2013","journal-title":"J. Infect. Public Health"},{"issue":"5","key":"10.1016\/j.parint.2025.103229_bb0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1179\/000349803225001373","article-title":"The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis","volume":"97","author":"Asilian","year":"2003","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"2","key":"10.1016\/j.parint.2025.103229_bb0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4269\/ajtmh.2009.80.172","article-title":"Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children","volume":"80","author":"Layegh","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.parint.2025.103229_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0019-5154.77549","article-title":"Decreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infection","volume":"56","author":"Sadeghian","year":"2011","journal-title":"Indian J. Dermatol."},{"issue":"3","key":"10.1016\/j.parint.2025.103229_bb0065","first-page":"502","article-title":"Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis","volume":"42","author":"Pourmohammadi","year":"2011","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"issue":"4","key":"10.1016\/j.parint.2025.103229_bb0070","first-page":"1","article-title":"Comparison of three methods for diagnosis of cutaneous leishmaniasis","volume":"5","author":"Pourmohammadi","year":"2010","journal-title":"Iran. J. Parasitol."},{"issue":"1","key":"10.1016\/j.parint.2025.103229_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007981","article-title":"Test accuracy of polymerase chain reaction methods against conventional diagnostic techniques for cutaneous Leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL: systematic review and meta-analysis","volume":"14","author":"Mesa","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.parint.2025.103229_bb0080","article-title":"Intra-species diversity of Leishmania major and L. tropica from clinical isolates of cutaneous Leishmaniasis in Southwest Iran inferred by ITS1-rDNA","volume":"48","author":"Aliyar","year":"2019","journal-title":"Iran. J. Public Health"},{"key":"10.1016\/j.parint.2025.103229_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1051\/parasite\/2022047","article-title":"Cutaneous leishmaniasis in Iran: a review of epidemiological aspects, with emphasis on molecular findings","volume":"29","author":"Nasiri","year":"2022","journal-title":"Parasite"},{"issue":"9\u201312","key":"10.1016\/j.parint.2025.103229_bb0090","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1080\/10826076.2010.484356","article-title":"HPLC detectors: a brief review","volume":"33","author":"Swartz","year":"2010","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.parint.2025.103229_bb0095","series-title":"Control of the Leishmaniases: Report of a Meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, 22-26 March 2010","author":"Leishmaniases WECotCot, Organization WH","year":"2010"},{"key":"10.1016\/j.parint.2025.103229_bb0100","series-title":"Cutaneous Leishmaniasis Control Guideline in Iran","author":"Shirzadi","year":"2012"},{"issue":"7","key":"10.1016\/j.parint.2025.103229_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010569","article-title":"Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: a randomized controlled clinical trial","volume":"16","author":"Javadi","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"10.1016\/j.parint.2025.103229_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006141","article-title":"Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation","volume":"12","author":"Olliaro","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.parint.2025.103229_bb0115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1468-3083.2010.03781.x","article-title":"Efficacy of CO2 laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate","volume":"25","author":"Shamsi Meymandi","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.parint.2025.103229_bb0120","first-page":"6462804","article-title":"A comparison between the effects of Glucantime, topical Trichloroacetic acid 50% plus Glucantime, and fractional carbon dioxide laser plus Glucantime on cutaneous Leishmaniasis lesions","volume":"2016","author":"Jaffary","year":"2016","journal-title":"Dermatol. Res. Pract."},{"issue":"9","key":"10.1016\/j.parint.2025.103229_bb0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1365-4632.2006.02822.x","article-title":"Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis","volume":"45","author":"Salmanpour","year":"2006","journal-title":"Int. J. Dermatol."},{"issue":"7","key":"10.1016\/j.parint.2025.103229_bb0130","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-4632.2009.04072.x","article-title":"Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis","volume":"48","author":"Firdous","year":"2009","journal-title":"Int. J. Dermatol."},{"issue":"12","key":"10.1016\/j.parint.2025.103229_bb0135","first-page":"6689","article-title":"The evaluation of intralesional glucantime and cryotherapy plus intralesional glucantime therapeutic efficacy on zoonotic cutaneous leishmaniasis: a randomized clinical trial","volume":"5","author":"Saghafipour","year":"2017","journal-title":"J. Pediatr. Perspect."},{"issue":"6","key":"10.1016\/j.parint.2025.103229_bb0140","first-page":"51","volume":"32","year":"2021","journal-title":"Comparison of effectiveness of oral fluconazole and intralesional glucantime in the treatment of cutaneous leishmaniasis Med. Forum"},{"issue":"2","key":"10.1016\/j.parint.2025.103229_bb0145","first-page":"348","article-title":"The efficacy of intralesional metronidazole compared to intralesional glucantime in the therapeutic therapy of cutaneous leishmaniasis","volume":"32","author":"Ullah","year":"2022","journal-title":"J. Pak. Assoc. Dermatol."},{"key":"10.1016\/j.parint.2025.103229_bb0150","doi-asserted-by":"crossref","first-page":"35089","DOI":"10.2340\/actadv.v104.35089","article-title":"Comparison of intralesional sodium stibogluconate versus intralesional meglumine antimoniate for the treatment of Leishmania major cutaneous leishmaniasis","volume":"104","author":"Solomon","year":"2024","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"10.1016\/j.parint.2025.103229_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011029","article-title":"Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: a collaborative retrospective study","volume":"17","author":"Castro","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"4","key":"10.1016\/j.parint.2025.103229_bb0160","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4269\/ajtmh.19-0531","article-title":"Clinical presentation and response to therapy in children with cutaneous leishmaniasis","volume":"102","author":"Suprien","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"12","key":"10.1016\/j.parint.2025.103229_bb0165","article-title":"Interventions for Old World cutaneous leishmaniasis","volume":"12","author":"Heras-Mosteiro","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.parint.2025.103229_bb0170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0019-5154.94279","article-title":"Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis","volume":"57","author":"Maleki","year":"2012","journal-title":"Indian J. Dermatol."},{"issue":"3","key":"10.1016\/j.parint.2025.103229_bb0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5812\/archcid.112222","article-title":"Comparative assessment of topical Glucantime\u00ae injection plus cryotherapy and cryotherapy alone for treatment of anthroponotic cutaneous Leishmaniasis","volume":"16","author":"Shirzadi","year":"2021","journal-title":"Arch. Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.parint.2025.103229_bb0180","article-title":"Systemic treatments of Leishmaniasis: a narrative review","volume":"6","author":"Taheri","year":"2019","journal-title":"Rev. Clin. Med."},{"issue":"11","key":"10.1016\/j.parint.2025.103229_bb0185","doi-asserted-by":"crossref","first-page":"740","DOI":"10.34172\/aim.2020.98","article-title":"Comparison of three different therapies for cutaneous leishmaniasis and identification of the etiologic isolates in Isfahan, Iran","volume":"23","author":"Abdellahi","year":"2020","journal-title":"Arch. Iran. Med."},{"issue":"4","key":"10.1016\/j.parint.2025.103229_bb0190","first-page":"278","article-title":"Comparison of intralesional Glucantime alone with intralesional Glucantime and levamizole in cutaneous leishmaniasis. Iranian","volume":"10","author":"Salmanpour","year":"2007","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.parint.2025.103229_bb0195","first-page":"718","article-title":"Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica: study protocol for a randomized, controlled trial","volume":"13","author":"Eskandari","year":"2021","journal-title":"Iran. J. Microbiol."},{"issue":"2","key":"10.1016\/j.parint.2025.103229_bb0200","first-page":"00011","article-title":"Successful treatment with Intralesional Meglumine Antimoniate in recurrent cutaneous Leishmaniasis: case report","volume":"1","author":"Natalia","year":"2017","journal-title":"J. Dermat. Cosmetol."},{"issue":"4","key":"10.1016\/j.parint.2025.103229_bb0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eri.10.19","article-title":"Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Goto","year":"2010","journal-title":"Expert Rev. Anti-Infect. Ther."},{"issue":"4","key":"10.1016\/j.parint.2025.103229_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105906","article-title":"Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review","volume":"55","author":"Santos","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.parint.2025.103229_bb0215","first-page":"61","article-title":"Field-deployable treatments for Leishmaniasis: intrinsic challenges, recent developments and next steps","volume":"14","author":"Pacheco-Fernandez","year":"2023","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.parint.2025.103229_bb0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12703\/r\/9-28","article-title":"An overview of the treatment of cutaneous leishmaniasis","volume":"9","author":"Garza-Tovar","year":"2020","journal-title":"Fac. Rev."},{"issue":"3","key":"10.1016\/j.parint.2025.103229_bb0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijpddr.2018.09.006","article-title":"Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis","volume":"8","author":"Alc\u00e2ntara","year":"2018","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"issue":"1","key":"10.1016\/j.parint.2025.103229_bb0230","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12982-024-00247-1","article-title":"Classical and innovative drugs for the treatment of Leishmania infections","volume":"21","author":"Mota","year":"2024","journal-title":"Discov. Public Health."},{"key":"10.1016\/j.parint.2025.103229_bb0235","first-page":"87","article-title":"Leishmania: an urgent need for new treatments","author":"eBioMedicine.","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.parint.2025.103229_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117109","article-title":"Enhancing the efficacy of fluconazole against Leishmania major: formulation and evaluation of FLZ-nanoemulsions for topical delivery","volume":"178","author":"Nahanji","year":"2024","journal-title":"Biomed. Pharmacother."}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576925002028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383576925002028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:53:24Z","timestamp":1769007204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383576925002028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"alternative-id":["S1383576925002028"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2025.103229","relation":{},"ISSN":["1383-5769"],"issn-type":[{"value":"1383-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the efficacy of Glucantime and determinants of treatment success in cutaneous leishmaniasis: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2025.103229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103229"}}